English | Español
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Patient Daily | May 7, 2023

Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Patient Daily | May 7, 2023

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Patient Daily | May 7, 2023

Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
Patient Daily | May 7, 2023

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
Patient Daily | May 7, 2023

Integra LifeSciences To Host Investor Day On May 4, 2023
Patient Daily | May 7, 2023

Integra LifeSciences Reports First Quarter 2023 Financial Results

Trending
Patient Daily | Sep 3, 2025

Top healthcare marketing experts to present at AOCOO-HNS 2025 virtual mid-year symposium, led by Greg Caesar of Medfluence Advisors
+ Pharmaceuticals
Patient Daily | Sep 4, 2025

PhRMA CEO on 340B abuse: ‘Big hospitals are abusing the 340B program to markup medicine prices’
+ Pharmaceuticals
Patient Daily | Aug 29, 2025

Deputy VP of Public Affairs of PhRMA on 340B: ‘Over 80% of all rural hospital beds were actually in urban hospitals’
+ Pharmaceuticals
Patient Daily | Sep 4, 2025

Baylor College of Medicine partners with Site Tx on immune-targeted drug discovery